-
Board Certification
American Board of Internal MedicineAmerican Board of Internal Medicine (Sub: Medical Oncology)National Board of Osteopathic Medical ExaminersPatient Rating
4.9 /5( out of 54 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety.
Patients are de-identified for confidentiality and patient privacy.August 06, 2023HUNTSMAN CANCER CENTERShe's a top notch doctor. Huntsman is fortunate to have her.
August 04, 2023HUNTSMAN CANCER CENTERGreat professional doctors
July 20, 2023SUGAR HOUSE HEALTH CENTERI always look forward to seeing Dr. Kerrigan. I have been her patient now for three years. She always answers my questions and explains everything about my lab results and scans. Shows me the pictures of my CT scans. She makes me feel better after our visit. I wouldn't trade her for anyone else...... THANK YOU SO MUCH!!!! Gracias!!!! See you in four months.......
April 13, 2023SUGAR HOUSE HEALTH CENTERShe is a wonderful caregiver she is honest and tells you the truth I had one doctor if I asked any thing he would say say I dont know he was not one of your doctors he is in a different clinic I never went back to him
March 28, 2023HUNTSMAN CANCER CENTERVery impressed with Dr. Kerrigan. She speaks directly to me about my care and the procedure.
March 25, 2023SUGAR HOUSE HEALTH CENTERShe has always been there for me. Answers all my questions and concerns. Wouldn't trade her for anyone else. Thank you so much. You have a special place in my heart.......
March 09, 2023SUGAR HOUSE HEALTH CENTERThe doctor listened to me and didn't even mind when I teased her.
February 24, 2023SUGAR HOUSE HEALTH CENTERWonderful!
February 15, 2023HUNTSMAN CANCER CENTERExcellent care, concern, explanations. I couldn't be more pleased with the care I received.
-
Board Certification and Academic Information
Academic Departments Internal Medicine -Primary Academic Divisions Oncology
Board Certification American Board of Internal MedicineAmerican Board of Internal Medicine (Sub: Medical Oncology)National Board of Osteopathic Medical ExaminersEducation history
Fellowship Hematology & Oncology - University of Utah School of Medicine Chief Fellow Hematology & Oncology - University of Utah School of Medicine Fellow Research Fellow Internal Medicine - Ohio State University Resident Research and Scholarly Advancement Fellowship (RSAF) program - Ohio University Heritage College of Osteopathic Medicine Research Fellow Doctoral Training Osteopathic Medicine - Ohio University Heritage College of Osteopathic Medicine D.O. Ohio State University B.S. Selected Publications
Journal Article
- McCrary HC, Aoki J, Huang Y, Chadwick B, Kerrigan K, Witt B, Hunt JP, Abraham D (2022). Mutation based approaches to the treatment of anaplastic thyroid cancer. Clin Endocrinol (Oxf), 96(5), 734-742. (Read full article)
- Fenlon JB, Hutten RJ, Weil CR, Lloyd S, Cannon DM, Kerrigan K, Cannon RB, Hitchcock YJ (2021). Comparing adjuvant radiation to adjuvant chemoradiation in postsurgical p16+ oropharyngeal carcinoma patients with extranodal extension or positive margins. Head Neck, 44(3), 606-614. (Read full article)
- Wang X, Kerrigan K, Puri S, Shen J, Akerley W, Haaland B (2022). Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data. Cancers (Basel), 14(3). (Read full article)
- Stetson PD, McCleary NJ, Osterman T, Ramchandran K, Tevaarwerk A, Wong T, Sugalski JM, Akerley W, Mercurio A, Zachariah FJ, Yamzon J, Stillman RC, Gabriel PE, Heinrichs T, Kerrigan K, Patel SB, Gilbert SM, Weiss E (2022). Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group. J Natl Compr Canc Netw, 1-6. (Read full article)
- Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, Patel S (2022). A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern. JTO Clin Res Rep, 3(3), 100280. (Read full article)
- Kerrigan K, Chan J, Vagher J, Kohlmann W, Naumer A, Anson J, Low S, Schiffman J, Maese L (2021). Lung Cancer in Li Fraumeni Syndrome. . JCO Precis Oncol, 23(5).
- Kerrigan K, Wang X, Haaland B, Adamson B, Patel S, Puri S, Akerley W (2021). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status. Clin Lung Cancer.
- Kerrigan K, Patel SB, Haaland B, Ose D, Chalmers AW, Haydell T, Meropol NJ, Akerley WL (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. 16(4), 313-323.
- Kerrigan K, Shoben A, Otterson G (2016). Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. Clin Lung Cancer, 17(6), 523-527. (Read full article)
- Kerrigan KOtterson G (2016). Evaluation of the Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients with Actionable Mutations Treated with Molecular Targeted Therapy in the Intensive Care Unit Setting. Am J Respir Crit Care Med.
Review
- Kerrigan K, Puri S (2022). Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer. [Review]. Curr Oncol Rep, 24(1), 113-123. (Read full article)
- Naqash AR, Kihn-Alarcon AJ, Stavraka C, Kerrigan K, Vareki M, Pinato DJ, Puri S (2021). The Role of Gut Microbiome in Modulating Response to Immune Checkpoint Inhibitor Therapy in Cancer. [Review]. Ann Transl Med.
Case Report
- Johnson ED, Kerrigan K, Butler K, Patel SB (2019). Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy. J Oncol Pharm Pract, 26(1), 224-227. (Read full article)
- Griswold CR, Kerrigan K, Patel SB (2019). Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report. Case Rep Oncol, 12(3), 866-871. (Read full article)
Abstract
- Owonikok TK, Elliot A, Dwivedi B, Ivanov A, Sica G, Kerrigan K, et al (2022). Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC) [Abstract].
- Russell J, Kerrigan K, Yang D (2022). Circulating tumor DNA profiling and serial analysis in salivary gland carcinomas reveal unique mutational subsets and actionable alterations [Abstract].
- Kerrigan K, Puri S, Sinnott JHaaland B, Akerley W, Patel SB (2021). Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis. [Abstract]. 16(3), 89.05.
- Kerrigan K, Chipman J, Jo Y, Haaland B, Johnson E, Puri S, Varghese T, Akerley W, Patel SB (2021). Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician’s Choice of First-line Platinum Chemotherapy. [Abstract]. 16(3 S122-123), OA09.05.
- Kerrigan K, Chipman J, Jo Y, Haaland B, Johnson E, Puri S, Varghese T, Akerley W, Patel SB (2021). Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Choice of Second-line Therapy. [Abstract]. 16(3, S199), FP05.01.
- Puri S, Patel S, Chalmers A, Kerrigan K, Cannon L, George S, Boucher K, Akerley W (2021). Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCLC [Abstract]. 16(3, S344), P15.02.
- Kerrigan K, Haaland B, Adamson B, Patel S, Akerley W (2019). Real-World Survival of Relapsed Compared to De-Novo Stage IV Diagnosis of Advanced Non-Small Cell Lung Cancer [Abstract]. 14(10), S307-308.
- Kerrigan K, Haaland B, Adamson B, Patel S, Akerley W (2019). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers [Abstract]. 14(10), P1.01-35.
Video/Film/CD/Web/Podcast
- Kerrigan K (2019). Incorporation PROs Can Improve Patient Care and Outcomes [Web]. OncLive Oncology Fellows Magazine.
-
News & Podcasts